Montalvo B M, Yrizarry J M, Casillas V J, Burke G W, Allouch M, Amendola M A, Seckinger D
Department of Radiology, University of Miami School of Medicine/Jackson Memorial Medical Center, FL 33136, USA.
J Vasc Interv Radiol. 1996 Jan-Feb;7(1):117-23. doi: 10.1016/s1051-0443(96)70746-7.
To determine the advantages of using transcatheter sclerotherapy to treat renal allograft-related lymphoceles.
Eighteen patients first seen with symptomatic lymphoceles secondary to renal transplantation were treated with povidone-iodine percutaneous sclerotherapy. Percutaneous catheters were place by means of sonographic, computed tomographic, or combined fluoroscopic and sonographic guidance. Sclerotherapy was initiated while patients were in the hospital, and the patients then instilled povidone-iodine twice a day at home.
One patient had an inadequate trial period of therapy and was not included in the analysis. Seventeen lymphoceles were adequately sclerosed. Average length of treatment was 35 days. Three lymphoceles recurred and were effectively treated percutaneously. Follow-up studies showed no recurrence 1 month to 2 years after completion of therapy. No patient needed surgery for lymphocele repair.
Because of its safety and efficacy, percutaneous transcatheter sclerotherapy with povidone-iodine should be the treatment of choice in patients with lymphoceles that develop after renal transplantation.
确定使用经导管硬化疗法治疗肾移植相关淋巴囊肿的优势。
18例首次因肾移植后继发症状性淋巴囊肿就诊的患者接受了聚维酮碘经皮硬化疗法治疗。经皮导管通过超声、计算机断层扫描或透视与超声联合引导放置。硬化疗法在患者住院期间开始，然后患者在家中每天两次注入聚维酮碘。
1例患者治疗试验期不足，未纳入分析。17个淋巴囊肿充分硬化。平均治疗时长为35天。3个淋巴囊肿复发并经皮有效治疗。随访研究显示治疗完成后1个月至2年无复发。无患者需要手术修复淋巴囊肿。
由于其安全性和有效性，聚维酮碘经皮经导管硬化疗法应成为肾移植后发生淋巴囊肿患者的首选治疗方法。
